INTS
Intensity Therapeutics, Inc. (INTS) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative TTM ROIC indicates capital is not earning peer-level returns, implying weaker structural efficiency than profitable semiconductor and equipment peers.
An extremely negative cash conversion cycle suggests very favorable working-capital timing, but the magnitude is likely distorted and less reliable than peers' operating metrics.
Very high current and quick ratios indicate ample liquidity, yet this supports resilience more than competitive positioning versus stronger cash-generating peers.
Weaknesses
Negative ROIC shows the business is destroying value on invested capital, leaving it structurally behind peers with sustained positive returns.
Net debt to EBITDA above 1.0x signals leverage remains meaningful relative to peers with stronger balance sheets and more consistent earnings power.
The absence of disclosed margin data limits confirmation, but the available return profile already implies weaker operating leverage than higher-quality peers.
Opportunities
If management converts liquidity into higher-return projects, the large cash buffer could support a faster repositioning than more constrained peers.
Working-capital efficiency, if sustained without distortion, could free cash for reinvestment and narrow the gap versus peers with slower cash cycles.
A cleaner balance-sheet profile than many leveraged peers could improve strategic flexibility if earnings quality stabilizes over the next two to five years.
Threats
Persistent negative returns on capital increase the risk that peers compound market share and scale advantages while INTS remains value-destructive.
Leverage combined with weak returns raises refinancing and covenant sensitivity relative to peers with stronger cash generation and lower funding risk.
If operating performance does not improve, the company may remain structurally disadvantaged versus peers that already convert capital into durable margins.
Overall Score
INTS appears structurally weak versus peers because negative capital returns and modest leverage outweigh liquidity support and leave limited evidence of durable competitive positioning.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Intensity Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
